Ancient proteins found in fossils up to 24 million years old
WASHINGTON (Reuters) -Scientists in recent years have made progress in finding ancient DNA in fossils, gaining insight into organisms that lived long ago. But the oldest DNA obtained so far dates back about two million years. Proteins, a cell's molecular machinery, also offer valuable information and have the virtue of surviving much longer, as new research shows.
Scientists have now extracted and sequenced proteins from dental fossils of extinct rhinoceroses, elephants and hippopotamuses, including from a rhino tooth 21-24 million years old. Separate research teams found protein fragments in fossils from vastly different environments - the frigid High Arctic of Canada and a scorching rift valley in Kenya.
"Together, these complementary projects demonstrate that proteins - fundamental building blocks of living organisms that preserve information about evolutionary history - can be found in ancient fossils the world over," said Harvard University evolutionary biologist Daniel Green, lead author of the Kenya fossils study published in the journal Nature.
This opens a new frontier for probing the deep evolutionary past, including the human lineage and perhaps even dinosaurs.
"Ancient proteins can tell us about an organism's evolutionary history by providing molecular data from specimens too old for DNA preservation. This allows researchers to clarify evolutionary relationships across the tree of life, even for species that went extinct millions of years ago," said Ryan Sinclair Paterson, a postdoctoral researcher at the University of Copenhagen's Globe Institute and lead author of the Canada fossil study in Nature.
DNA and proteins are fragile and degrade over time, but proteins are more resilient. The oldest-known DNA is from organisms that lived in Greenland two million years ago. Until now, the oldest-known proteins preserved well enough to offer insight on evolutionary relationships were about four million years old, from the Canadian Arctic.
The new research pushes the boundaries of ancient protein research, a field called paleoproteomics, back by millions of years.
Proteins were obtained from teeth of five rhino, elephant and hippo species that lived 1.5–18 million years ago in Kenya's Turkana region. The proteins showed the ties between the ancient animals and their modern-day relatives.
Proteins also were extracted from a fragment of a tooth of an extinct rhino unearthed at a site called Haughton Crater in Nunavut, Canada's northernmost territory, that was up to 24 million years old. They showed how this species fit into the rhino family tree.
Haughton Crater's cold and dry conditions were considered ideal for preserving proteins. Preservation in the hot climate of Turkana was more unexpected.
DNA and proteins, fundamental molecules in biology, possess distinct structures and functions. Deoxyribonucleic acid is the blueprint for life, bearing instructions for an organism's development, growth and reproduction. Proteins perform numerous functions based on instructions from DNA.
"Proteins are encoded by our genetic code, DNA, so protein sequences reveal information about relatedness between different individuals, and biological sex, among other things," Green said.
The scientists extracted peptides - chains of organic compounds called amino acids that combine to form proteins - found inside tooth enamel.
"Some proteins help build teeth, the hardest and most durable structures in animal bodies," Green added.
"Enamel is mostly rock: a mineral called hydroxyapatite. But its formation is biologically mediated by proteins that guide both shape and hardness over time. Because these proteins become entombed deep within enamel mineral, we have some reason to expect that protein fragments can be preserved over many millions of years," Green said.
Homo sapiens appeared about 300,000 years ago. Ancient proteins previously have been found in the teeth of some extinct species in the human evolutionary lineage, called hominins. The Turkana region has yielded important hominin fossils.
"Hominins have evolutionary origins and/or diversification in the area where our samples derive, so our results have promise in future exploration of the enamel proteome (set of proteins) of our evolutionary ancestors from the Turkana Basin of Kenya," said study co-author Timothy Cleland, a physical scientist at the Smithsonian Museum Conservation Institute in Maryland.
The proteins studied came from large-bodied species dating to the age of mammals that followed the demise of the dinosaurs that had dominated during the preceding Mesozoic era, which ended 66 million years ago.
Green said that in the new research the number of detectable proteins declined in progressively older fossils. But Green did not rule out finding proteins dating to the age of dinosaurs, saying, "Newer and better methods for extracting and detecting ancient proteins could, perhaps, push paleoproteomics into the Mesozoic."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau. 'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.' Key Scientific Sessions and Presentations: Lecanemab Clarity AD OLE in Early AD: Initial Findings from 48-Month AnalysisWednesday, July 30, 8:00–8:45 AM ET Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's DiseaseWednesday, July 30, 9:00–10:30 AM ET Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous DeliverySunday, July 27, 8:00–8:45 AM ET Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway LearningsSunday, July 27, 9:00–10:30 AM ET Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported ResultsSunday, July 27, 4:14–5:45 PM ET Innovations in Tau Therapies and Biomarkers for Alzheimer's Disease: Bridging Research and Clinical PracticeWednesday, July 30, 2:00–3:30 PM ET Baseline Characteristics from CELIA: A Phase 2 Study to Evaluate BIIB080 in Participants with Early Alzheimer's DiseaseMonday, July 28, 7:30 AM–4:15 PM ET Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on building on the resources already available. For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth. About BIIB080BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis. About LEQEMBI ® (lecanemab)LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term routinely post information that may be important to investors on our website at Follow us on social media - Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. MEDIA CONTACT:BiogenMadeleine Shin+ 1 781 464 INVESTOR CONTACT:BiogenTim Power+1 781 464 2442IR@ Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
an hour ago
- Yahoo
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau. 'At AAIC, we are sharing data that underscore our ongoing efforts to advance both how Alzheimer's is treated and how care is delivered, including 48-month findings from the LEQEMBI Clarity AD open-label extension and new insights into the potential of subcutaneous maintenance dosing for LEQEMBI. We are also excited to share baseline characteristics from CELIA, our Phase 2 study of BIIB080, an investigational ASO therapy targeting tau,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'As we deepen our understanding of this complex disease, we remain committed to pushing the science forward and evolving care to better meet the needs of patients and families.' Key Scientific Sessions and Presentations: Lecanemab Clarity AD OLE in Early AD: Initial Findings from 48-Month AnalysisWednesday, July 30, 8:00–8:45 AM ET Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's DiseaseWednesday, July 30, 9:00–10:30 AM ET Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous DeliverySunday, July 27, 8:00–8:45 AM ET Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway LearningsSunday, July 27, 9:00–10:30 AM ET Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported ResultsSunday, July 27, 4:14–5:45 PM ET Innovations in Tau Therapies and Biomarkers for Alzheimer's Disease: Bridging Research and Clinical PracticeWednesday, July 30, 2:00–3:30 PM ET Baseline Characteristics from CELIA: A Phase 2 Study to Evaluate BIIB080 in Participants with Early Alzheimer's DiseaseMonday, July 28, 7:30 AM–4:15 PM ET Educational Program on Tau in Alzheimer's Disease At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer's disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on building on the resources already available. For more information, please see the AAIC 2025 program and visit the Biogen AAIC booth. About BIIB080BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer's disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer's disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO). BIIB080 was discovered by Ionis. About LEQEMBI ® (lecanemab)LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). LEQEMBI is an amyloid beta-directed antibody for the treatment for Alzheimer's disease (AD) in the U.S. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term routinely post information that may be important to investors on our website at Follow us on social media - Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements, including about the potential clinical effects of lecanemab and BIIB080; the potential benefits, safety and efficacy of lecanemab and BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated risks, benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab and BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; risks associated with third party collaborations; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks of unexpected costs or delays or other unforeseen hurdles; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. MEDIA CONTACT:BiogenMadeleine Shin+ 1 781 464 INVESTOR CONTACT:BiogenTim Power+1 781 464 2442IR@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Are You Self-Sabotaging Your Hormone Therapy?
If you've been navigating the ups and downs of estrogen in midlife, you've probably heard the names: estradiol, estrone and estriol—the three main types of estrogen in the body. But new research is turning the spotlight onto another form of estrogen that may play a bigger role than previously thought—2-hydroxyestrone, sometimes referred to as a 'protective' estrogen. In a recent study published in Menopause: The Journal of The North American Menopause Society, researchers looked at how a naturally derived supplement called 3,3′-diindolylmethane (DIM), a compound found in vegetables like broccoli and Brussels sprouts, may help shift estrogen metabolism in a beneficial direction. Specifically, they found that DIM supplementation increased levels of 2-hydroxyestrone while reducing levels of 16α-hydroxyestrone, a form of estrogen some studies have linked to increased breast cancer risk. More from Flow Space Why Midlife Women Are More Likely to Experience This Painful GI Condition So what does this mean for your hormones, your health and your hot flashes? Here's what experts say you should know about DIM, 'good' estrogens and the future of hormone support in midlife and beyond. That 'Natural' Supplement Might Be Messing With Your Hormones DIM is a compound your body produces when you digest cruciferous vegetables like broccoli, kale and cabbage. It's been turned into a supplement and heavily promoted online as a way to 'detox' estrogen, clear hormonal acne or 'balance' hormones during perimenopause and menopause. But in supplement form, you're often getting much higher doses than you'd ever get from eating vegetables, and that can affect how your body processes hormones like estrogen. 'I like to say estrogen is a 'use it and lose it' hormone meaning you want to get the benefit of the estrogen, but you don't want it lingering in the body longer than it needs to because then it starts to accumulate and cause issues,' Dr. Stephanie Wallman, medical director at The Lanby, tells Flow Space. 'For menopausal women, who don't have much naturally cycling estrogen, there is not as much estrogen around and therefore do not require DIM to help move estrogen out of the body.' In other words, if you're using DIM during menopause, it may disrupt hormone balance rather than restore it, especially in women already dealing with fluctuating or low estrogen levels. And for women using hormone therapy, you may be undermining your own treatment without realizing it. That could explain sudden changes in how you feel—like hot flashes returning, mood dips or other symptoms flaring up again. Some experts also caution that while altering estrogen metabolism may reduce certain risks (like estrogen-sensitive cancer), the long-term effects of sustained DIM use—especially in high doses—haven't been well studied. 'Each woman is programmed through their genes and environmental factors to process (detoxify) estrogen differently,' says Wallman. 'If a woman is predisposed to hold on to estrogen more or to process it through a less desirable pathway, this will still happen during menopause.' Other Side Effects of DIM You've probably seen the promises: DIM will 'balance your hormones,' 'detox estrogen' and 'support healthy metabolism.' But what's actually happening under the surface is far more nuanced, and for women in midlife, it's worth a closer look. For starters, DIM doesn't remove toxins. 'Detoxify sounds appealing, but it's not a scientific term here,' Dr. Neha Pathak, chief physician editor at WebMD, tells Flow Space. 'DIM doesn't remove anything from the body, it just changes how estrogen is broken down.' That might be helpful in some cases, but it's not inherently good or bad; it depends on your body, your symptoms and your overall hormonal profile. When estrogen is metabolized, it can take different 'routes' in the body. Some metabolites—like 2-hydroxyestrone—are considered gentler and possibly protective, while others—like 16α-hydroxyestrone—may be more active or linked to cancer risk. DIM pushes metabolism toward the former. But experts caution that we don't fully understand what those changes mean in the long run. 'It's more complex than just 'good' or 'bad' estrogen,' says Pathak. 'We still have a lot to learn about what these changes really mean for long-term health.' Another gray area? Cancer prevention. While some studies suggest that certain estrogen breakdown patterns are associated with a lower risk of breast cancer, there's no strong evidence that taking DIM as a supplement will actually reduce your risk. 'That's still a big question mark,' says Pathak. 'We don't know if trying to manipulate estrogen metabolism in this way leads to better outcomes.' Talk to Your Doctor Before Mixing Supplements with Hormone Therapy Many women start taking DIM often without realizing it could impact their hormones in significant ways. And many never bring it up with their doctor. But that silence can be risky, even if you're not on hormone therapy. 'DIM works very well and has become very popular among supplements that women try on their own,' says Wallman. 'But it can also cause side effects that are not so obviously tied to taking DIM, so I certainly recommend that doctors understand what DIM is—and what you can expect to happen when someone starts using it.' The issue is that DIM doesn't behave like a harmless vitamin. It influences how your body breaks down estrogen, sometimes shifting the balance of estrogen metabolites in unpredictable ways. That might be helpful in some situations, but it could also affect mood, sleep or energy levels, and even change how other medications or hormone therapies work. 'In my practice, no one walks out without me knowing everything about their hormones, so I'm certainly asking about DIM,' says Wallman. 'But many practitioners are not—and they should be.' Before adding anything new to your wellness regimen, talk to your healthcare provider, ideally someone who's experienced with menopause, perimenopause or hormone health. The goal isn't just to get a green light, it's to make sure the supplement actually makes sense for your body, your symptoms and your treatment plan. Pathak, suggests bringing a few key questions to your appointment: Do I really need this? Could it affect other medications or supplements I'm taking? Can I get similar benefits from diet instead? How will we track if it's helping—or doing more harm than good? Because while DIM may support healthy hormone metabolism in certain situations, it's not a one-size-fits-all solution. Your needs in midlife are unique—and so is your hormonal landscape.